Drug Trial Radar · NCT06734208
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Jan 31, 2025
Primary completion
Nov 27, 2025
Study completion Nov 27, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.
Conditions
- Hepatic Impairment
Interventions
DivarasibDrug
Divarasib will be administered as a single oral dose as specified for the respective cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of DivarasibTime frame: Day 1 to Day 7
- Maximum Observed Concentration (Cmax) of DivarasibTime frame: Day 1 to Day 7
- Area Under the Concentration-time Curve from Hour 0 to the last measurable concentration (AUC0-t) of DivarasibTime frame: Day 1 to Day 7
- Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of DivarasibTime frame: Day 1 to Day 7
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami, Inc.
Miami, Florida
Panax Clinical Research, LLC
Miami Lakes, Florida
Orlando Clinical Research Center
Orlando, Florida
American Research Corporation Inc.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.